Furthermore, both CD5- and CD19-NSCAR (non-signaling CARs) modified γδ T cells demonstrated a significant increase in killing T-ALL and B-ALL cell lines, respectively [237]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.